🇺🇸 FDA

Intelligence · Clinical Pipeline

SANGAMO THERAPEUTICS Pipeline

All ClinicalTrials.gov programs at SANGAMO THERAPEUTICS — phase, modality, and trial IDs.

Programs
25

Quick answer

SANGAMO THERAPEUTICS has 25 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. TX200-TR101

    SANGAMO THERAPEUTICS, INC

    Kidney Transplant Rejection

    phase 3 small molecule active

    1 trial

  2. CERE-110: Adeno-Associated Virus injection Surgery

    SANGAMO THERAPEUTICS, INC

    Alzheimer's Disease

    phase 2 small molecule completed

    1 trial

  3. CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN])

    SANGAMO THERAPEUTICS, INC

    Idiopathic Parkinson's Disease

    phase 2 small molecule completed

    1 trial

  4. CERE-120: Adeno-Associated Virus Delivery of Neurturin

    SANGAMO THERAPEUTICS, INC

    Idiopathic Parkinson's Disease

    phase 2 mab completed

    1 trial

  5. Plerixafor

    SANGAMO THERAPEUTICS, INC

    Sickle Cell Disease

    phase 2 mab completed

    1 trial

  6. SB-318

    SANGAMO THERAPEUTICS, INC

    MPS I

    phase 2 mab terminated

    1 trial

  7. SB-509

    SANGAMO THERAPEUTICS, INC

    Diabetes Mellitus, Type 1

    phase 2 small molecule completed

    4 trials

  8. SB-509

    SANGAMO THERAPEUTICS, INC

    Amyotrophic Lateral Sclerosis

    phase 2 small molecule completed

    1 trial

  9. SB-728-T

    SANGAMO THERAPEUTICS, INC

    HIV

    phase 2 gene therapy completed

    2 trials

  10. SB-728mR-T

    SANGAMO THERAPEUTICS, INC

    Human Immunodeficiency Virus (HIV)

    phase 2 gene therapy completed

    1 trial

  11. SB-913

    SANGAMO THERAPEUTICS, INC

    Mucopolysaccharidosis II

    phase 2 mab terminated

    1 trial

  12. ST-400 Investigational product

    SANGAMO THERAPEUTICS, INC

    Transfusion Dependent Beta-thalassemia

    phase 2 gene therapy completed

    1 trial

  13. ST-503

    SANGAMO THERAPEUTICS, INC

    Chronic Neuropathic Pain

    phase 2 gene therapy active

    1 trial

  14. ST-920

    SANGAMO THERAPEUTICS, INC

    Fabry Disease (X-linked lysosomal storage disease).

    phase 2 small molecule active

    1 trial

  15. ST-920

    SANGAMO THERAPEUTICS, INC

    Fabry Disease (X-linked lysosomal storage disease).

    phase 2 small molecule active

    1 trial

  16. ST-920

    SANGAMO THERAPEUTICS, INC

    Fabry Disease

    phase 2 mab completed

    1 trial

  17. TX200-TR101

    SANGAMO THERAPEUTICS, INC

    Kidney Transplant Rejection

    phase 2 mab active

    1 trial

  18. TX200-TR101

    SANGAMO THERAPEUTICS, INC

    Prophylaxis against renal transplant rejection

    phase 2 small molecule active

    1 trial

  19. CERE-110: Adeno-Associated Virus Delivery of NGF

    SANGAMO THERAPEUTICS, INC

    Alzheimer's Disease

    phase 1 gene therapy completed

    1 trial

  20. CERE-120: AAV2-NTN

    SANGAMO THERAPEUTICS, INC

    Parkinson's Disease

    phase 1 gene therapy completed

    1 trial

  21. SB-728-T

    SANGAMO THERAPEUTICS, INC

    HIV Infection

    phase 1 gene therapy completed

    1 trial

  22. SB-728mR-HSPC Infusion 3 days following busulfan conditioning

    SANGAMO THERAPEUTICS, INC

    HIV

    phase 1 gene therapy active

    1 trial

  23. SB-FIX

    SANGAMO THERAPEUTICS, INC

    Hemophilia B

    phase 1 mab terminated

    1 trial

  24. ZFN modified T cells

    SANGAMO THERAPEUTICS, INC

    HIV

    phase 1 mab completed

    1 trial

  25. hVEGF-A

    SANGAMO THERAPEUTICS, INC

    Diabetic Neuropathy

    phase 1 gene therapy completed

    1 trial

Frequently asked questions

How many pipeline programs does SANGAMO THERAPEUTICS have?

25 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.